Objectives: Osteoporosis (OP) is a usual disease with a possible genetic predisposition. IL-23 plays a role in physiological bone remodeling and regulates the activity of cells of the bone either directly or indirectly on bone-resorbing osteoclasts as well as on bone-forming osteoblasts. Recent animal and human trials have revealed the main pro-osteoclastogenic activities for the IL-23 pathway. We examined nine single nucleotide polymorphisms (SNPs) in the interleukin-23 receptor (IL-23R) in 100 OP patients and gender- and age-matched 96 healthy volunteers. The most analyzed SNPs in the recent rheumatology literature were selected.
Methods: In addition to gene polymorphisms several laboratory parameters (osteocalcin, parathormone, vitamine D) were investigated. Independent Samples t-test and Mann-Whitney-U test were used to compare several demographic and clinical parameters between the groups. P-value < 0.05 was accepted to be statistically significant.
Results: Having the heterozygous GA genotype of IL-23R rs1004819 and the heterozygous CT genotype of Il-23R rs7530511 significantly increase the risk of developing OP (adjusted OR: 3.51, p = 0.031 and OR: 2.41, p = 0.027, respectively). The wild homozygous GG genotype of Il-23R rs11209032 had higher osteocalcin levels compared with the mutant homozygous AA genotype (18.75 ± 9.76, p = 0.009).
Conclusions: Our findings suggest that several IL-23R gene polymorphisms are seen more often in osteoporosis patients than in healthy volunteers. In addition, some SNPs were related to higher serum osteocalcin levels.
This study was supported by the decision of Pamukkale University Scientific Research Projects Coordination Unit, dated 11/02/2014 and 2014TPF001.
We would like to thank Dr Ergün Soysal and Dr Emre Tepeli for their contributions.
|Konular||Romatoloji ve Artrit|
|Erken Görünüm Tarihi||1 Haziran 2023|
|Yayımlanma Tarihi||4 Kasım 2023|
|Gönderilme Tarihi||4 Mart 2022|
|Kabul Tarihi||13 Haziran 2022|
|Yayımlandığı Sayı||Yıl 2023 Cilt: 9 Sayı: 6 - November 2023|